Johnson & Johnson
NEW BRUNSWICK, NJ
SELEXIPAG (selexipag) by Johnson & Johnson is prostacyclin receptor agonists [moa]. First approved in 2023.
Drug data last refreshed 20h ago
Prostacyclin Receptor Agonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
Worked on SELEXIPAG at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.